This site and its domain are for sale. Email the owner if you want to talk about it.

bariatricalt.com

The Gastric Sleeve: The World's Most Common Weight-Loss Operation

The world's most popular weight-loss operation often becomes a different operation later, and the evidence on why is more tangled than the index-card theory.

Surgical instruments and a simple diagram of a stomach reshaped into a narrow tube on a clean table.

The most common weight-loss operation on Earth is one that a large share of its own patients later have turned into a different operation. The authors of a seven-year study comparing two revision surgeries describe sleeve gastrectomy as “currently the most performed bariatric procedure worldwide,” and the same study says that “up to half of sleeve gastrectomy patients may require conversion surgery due to insufficient weight loss, weight recurrence, or complications.” That is the whole story, really, but it takes a while to explain.

Here is the plain version. A gastric sleeve, or laparoscopic sleeve gastrectomy, reshapes the stomach into a narrow tube by removing part of it (the “ectomy” means what it sounds like). One review puts the sleeve’s weight loss at 25 to 30% of total body weight at two to five years, and a review of very long-term outcomes puts it at 24.4% at ten years. The main trade-off is acid reflux, which in a randomized trial was far more common after a sleeve than after a gastric bypass, and the main competitor on weight is now a drug.

What a gastric sleeve actually is, and why that is not obvious

The sensible reaction to all this is: the stomach is smaller, so you eat less, so you weigh less. That is a perfectly good theory. It fits on an index card. It is also not quite how anyone in the field describes it.

The useful contrast is with endoscopic sleeve gastroplasty, which a narrative review describes as creating “a tubular gastric sleeve without resection, preserving native anatomy” (stitches from the inside, nothing removed). The surgical sleeve gets to roughly the same shape by actually taking stomach out. You would expect two tubes of similar shape to do similar things. They do not: the review of restrictive surgery puts the endoscopic version at 13 to 16% total weight loss at twelve months, against that 25 to 30% for the surgical one.

So shape is not the whole thing. A review in Clinical Diabetology says metabolic improvement after bariatric surgery comes from “both weight loss-dependent effects and surgery-specific mechanisms that are independent of weight loss.” Translated: the operation does something beyond making you eat less, and the something is not fully pinned down. One research group got far enough into the question to build a computational model of a sleeved stomach, called StomachSim, to simulate how food gets digested and emptied. The most popular operation in the world has a physics engine.

How much weight the sleeve takes off

Before the numbers, a point of procedure. For the avoidance of doubt, this field reports weight loss in two currencies, and they must not be commingled. “Total weight loss” is the share of your starting weight that is gone. “Excess weight loss” is the share of the weight above some notional target that is gone, which is a bigger-looking number describing the same pounds. A 50% excess weight loss and a 25% total weight loss can be the same patient on the same morning. Readers who compare one to the other do so at their own risk.

With that settled: the long-run sleeve is a mid-20s total weight loss operation. A German randomized trial found 27.4% total weight loss at five years after a standard sleeve, and 31.6% after a “banded” sleeve (one with a ring placed around the tube). The Norwegian Oseberg trial found 17.2% at five years for the sleeve against 22.2% for gastric bypass. The Finnish SLEEVEPASS trial found bypass ahead at ten years too, 51.9% versus 43.5% excess weight loss.

An Italian study of 131 sleeve patients found that men lost more kilograms than women at twelve months (36.6 versus 31.2) but the same percentage of their weight. This is what percentages are for. Bigger people losing bigger absolute amounts is arithmetic, not biology.

The reflux trade-off, measured

The Oseberg trial is the cleanest evidence here, and it is small. It enrolled 109 people with type 2 diabetes between October 15, 2012, and September 1, 2017, put 55 into sleeves and 54 into bypasses, kept it triple-blind, and finished in December 2022. Nobody died in either group.

The headline difference was reflux. Pathological acid reflux, meaning reflux bad enough to show up on testing, was more common after the sleeve by a risk difference of 51.1 percentage points (with a confidence interval running from 28.0 to 74.2, which is wide, but its low end is still large). Bypass, on the other hand, had its own cost: symptomatic low blood sugar after meals in 28% of bypass patients versus 2% of sleeve patients. To be fair to the sleeve, that is a real point in its column.

The same trial found diabetes remission at five years in 63% of bypass patients versus 30% of sleeve patients. (That fight gets its own article on this site.) A meta-analysis of a different hybrid, the single anastomosis sleeve ileal bypass, found it beat the plain sleeve on excess weight loss by 9.61 points. Surgeons keep finding things to bolt onto the sleeve. That is sort of a vote.

Why so many sleeves become something else

A Polish ten-year study, BARI-10-POL, found that 24.3% of sleeve patients needed a revisional procedure over ten years. Adjustable gastric banding, in the same study, needed revision 100% of the time. Against that bar the sleeve looks great.

The Danish BARI-STEP trial enrolled people at least a year after a sleeve or bypass who had “a suboptimal clinical response.” Put flatly, the surgery had not worked as well as everyone wanted. That group is large enough to run trials on, which tells you something about its size.

What happens to them? A multicenter retrospective study looked at 4,901 sleeve patients with insufficient loss or regain: 3,004 converted to bypass, 1,897 added a GLP-1 drug. At three years, conversion bypass got 26.1% total weight loss versus 13.7% for the drug group. Starting weights were statistically indistinguishable (p = 0.993). It is not randomized, though, so who chose what, and why, is not settled. A separate meta-analysis found a duodeno-ileal bypass beat a one-anastomosis bypass as a revision at one year, and a seven-year study found iron deficiency more common after the one-anastomosis version. There is, in other words, a whole menu for the second course.

Here is an invented scenario, clearly made up. A hospital builds a sleeve clinic on the first floor and a revision clinic on the second. The first-floor surgeon finishes a case and tells the patient, “Great result, see you upstairs in five or so years, maybe.” The second floor does well enough to add a third floor for revisions of revisions. Eventually the elevator is the most profitable piece of medical equipment in the building, and the hospital’s annual report lists it as a procedure.

Where the drugs come in

Look, this is the part that changed the conversation. A network meta-analysis of 23 randomized trials covering 14,293 people found tirzepatide at 10 or 15 mg produced 21.3% total weight loss, statistically equivalent to the sleeve’s 21.1%. The sleeve’s confidence interval there runs from 14.2% to 28.0%, which is a lot of room. A 2026 systematic review, on the other hand, said tirzepatide 15 mg “approached but did not match” sleeve benchmarks at 72 weeks. So whether a drug equals the sleeve is not settled. It depends which pile of studies you trust.

The relationship between sleeve and drug has also gotten blurry. Plenty of sleeve patients now also see a GLP-1 on the side, an arrangement the literature politely calls “adjuvant.” Everyone involved seems to know about it. The head-to-head comparison is covered in its own piece on this site, for instance, where the units get the care they need.

So why is it the most common one

The facts here do not explain the sleeve’s popularity. They establish that it is popular, that bypass beats it on weight and diabetes in trials, that it causes more reflux, and that a quarter to half of patients may need something more later. Why the world settled on it anyway is not answered by any of these studies.

The nearest analogy is the most popular car in a country, which is rarely the fastest or the safest and is usually the one that is good enough at most things. I guess the sleeve is the Camry of surgery. Anyway, if up to half of sleeves become something else, then one of the busier routes to a gastric bypass is to first choose the operation that is specifically not a gastric bypass.

Sources

  1. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.
  2. A Comprehensive Review of Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, One-Anastomosis Gastric Bypass, Duodenal Switch, and SADI-S: Very Long-Term Outcomes at 10 Years and Beyond
  3. Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study
  4. Seven-Year Comparative Outcomes of One Anastomosis Gastric Bypass and Roux-en-Y Gastric Bypass for Weight Recurrence Regain Post Sleeve Gastrectomy
  5. Shaping the Future of Restrictive Bariatric Surgery: Clinical, Economic, and Long-Term Perspectives on Endoscopic and Laparoscopic Sleeve
  6. Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review
  7. Banded Versus Non-banded Sleeve Gastrectomy: 5-Year Results of a 3-Year Randomized Controlled Trial
  8. Incretin-Based Therapies Versus Bariatric and Metabolic Surgery for Obesity and Type 2 Diabetes Mellitus: A Head-to-Head Systematic Review of Glycaemic, Cardiovascular, Hepatic, Weight, and Quality-of-Life Outcomes
  9. Gender Differences in Weight Loss Extent Following Bariatric Surgery
  10. Laparoscopic Single Anastomosis Duodeno-Ileal Bypass Versus One Anastomosis Gastric Bypass as Revisional Procedures after Sleeve Gastrectomy: Meta-analysis and Systematic Review
  11. GERD remission and safety profile of Single Anastomosis Sleeve Ileal (SASI) bypass vs sleeve gastrectomy (SG): a systematic review and meta-analysis
  12. Long-term outcomes of metabolic bariatric surgery: a 10-Year multicenter retrospective study in Poland (BARI-10-POL)
  13. Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial
  14. Scholars@Duke publication: Patient-reported outcomes, weight loss, and remission of type 2 diabetes 3 years after gastric bypass and sleeve gastrectomy (Oseberg); a single-centre, randomised controlled trial.
  15. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial
  16. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
  17. [2411.18586v2] Modeling the Effect of Sleeve Gastrectomy on Gastric Digestion in the Stomach: Insights from Multiphase Flow Modeling
  18. Endoscopic Sleeve Gastroplasty: A Qualitative Narrative Review of Outcomes, Safety, and Clinical Applications
  19. Bariatric Surgery and Type 2 Diabetes Remission and Relapse: Mechanisms, Predictive Factors, and Postoperative Management — a Review Article | Ciesielska | Clinical Diabetology

Bariatric Alt explains published research. It is not medical advice, and it never recommends a surgeon, a clinic, a dose or a product. Talk to a clinician about which option fits you.

Read next